Elixiron Immunotherapeutics (Cayman) Limited
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
1. Precision Immunotherapy
Develops therapies that precisely modulate disease-specific immune imbalances by targeting key pathways and biomarkers to address root causes.
2. mRNA Therapeutics Platform
Uses mRNA to direct in-vivo production of therapeutic proteins, enabling highly targeted treatments across applications from cancer immunotherapy to gene editing, while reducing development time and cost
Develops therapies that precisely modulate disease-specific immune imbalances by targeting key pathways and biomarkers to address root causes.
2. mRNA Therapeutics Platform
Uses mRNA to direct in-vivo production of therapeutic proteins, enabling highly targeted treatments across applications from cancer immunotherapy to gene editing, while reducing development time and cost
Founded Year
2025
Unified Business No.
60600720
Status
Active
Number of Employees
0
Total Paid-in
Capital
0 (NT$)
Exit Status
Emerging Stock Exchange(2026)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Elixiron Immunotherapeutics focuses on developing precision immunotherapies targeting neuroinflammation, autoimmune diseases, and cancer. Leveraging deep expertise in immunology and drug development, the company has advanced two high-potential lead candidates into clinical trials: EI-1071 (Enrupatinib), for Alzheimer’s disease, ALS, Parkinson’s disease, and idiopathic pulmonary fibrosis, and EI-001 (Indemakitug), for vitiligo, hemophagocytic syndrome, and alopecia areata.
